Bendamustine and Melphalan in Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 20, 2017

Primary Completion Date

March 12, 2020

Study Completion Date

May 28, 2020

Conditions
Multiple Myeloma
Interventions
DRUG

Melphalan

High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive melphalan at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day on days -2 and -1, with the ASCT at day 0.

DRUG

Bendamustine

High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive bendamustine at a total dose of 400mg/m2, divided in two doses of 200mg/m2/day on days -4 and -3. Melphalan is given at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day, each on days -2 and -1, with the ASCT at day 0.

Trial Locations (1)

3010

Department for Medical Oncology University Hospital/Inselspital, Bern

All Listed Sponsors
collaborator

Mundipharma Medical Company

INDUSTRY

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT03187223 - Bendamustine and Melphalan in Myeloma | Biotech Hunter | Biotech Hunter